Attovia Therapeutics, Inc. reports initial insider ownership by Vida Ventures funds through holdings of Series C Preferred Stock, which is convertible into Common Stock on a 9.29-for-1 basis with no expiration date. Upon the closing of an initial public offering of Common Stock, all Series C Preferred shares will automatically convert into Common Stock on the same 9.29-for-1 basis without additional consideration. Vida Ventures III, L.P. holds indirect interests in 937,265 underlying Common shares, and Vida Ventures III-A, L.P. holds indirect interests in 2,160 underlying Common shares. The general partner and its investment committee members may be deemed to share voting and investment power but disclaim beneficial ownership beyond any pecuniary interest.
Attovia Therapeutics, Inc. director Angie You reported initial equity holdings. The filing lists 52,852 shares of Common Stock held directly and a stock option for 19,913 shares of Common Stock at an exercise price of $4.9237 per share, expiring on May 17, 2035. Footnotes describe three-year vesting schedules, with portions of the options vesting annually through July 29, 2027 and May 18, 2028, conditioned on continued service.
Attovia Therapeutics, Inc. lists initial equity holdings for Chief Scientific Officer Petter Veiby. He directly holds 104,951 shares of Common Stock. He also holds four stock option awards over Common Stock: 5,382 shares at an exercise price of $2.8799 expiring March 5, 2034; 107,642 shares at $3.5302 expiring May 8, 2034; 89,343 shares at $4.9237 expiring May 17, 2035; and 18,837 shares at $1.5793 expiring August 16, 2033. Each option vests over four years, with 25% vesting on specified initial dates in 2024–2026 and the remaining 75% vesting in equal monthly installments over three years, subject to continued service.
Attovia Therapeutics, Inc. director Royston Aaron filed an initial ownership report on Form 3. The filing lists his status as a director but does not report any equity transactions or current holdings, and no Rule 10b5-1 trading plan is indicated.
Attovia Therapeutics, Inc. reported initial insider holdings showing a Chief Financial Officer with two stock option awards over its common stock. One option covers 215,285 underlying shares at an exercise price of $3.5302 per share, expiring on November 13, 2034. The second option covers 80,731 underlying shares at an exercise price of $4.9237 per share, expiring on May 17, 2035. Each option vests over four years, with 25% of the underlying shares vesting on an initial vesting date and the remaining 75% vesting in 1/48th monthly installments over three years, subject to continued service.
Attovia Therapeutics, Inc. reported the initial equity holdings of Chief Business Officer Zaneta Odrowaz. She directly holds 103,269 shares of common stock, including 17,156 unvested shares that continue to vest monthly and are scheduled to be fully vested on April 27, 2027, subject to continued service. She also holds stock options to purchase common stock, including options over 15,137 shares at $1.5793 per share expiring on August 16, 2033, 5,382 shares at $2.8799 expiring on March 5, 2034, 102,260 shares at $3.5302 expiring on May 8, 2034, and 85,037 shares at $4.9237 expiring on May 17, 2035. Each option vests over four years, with 25% vested on specified initial vesting dates and the remaining shares vesting in equal monthly installments over three years, contingent on continued service.
Attovia Therapeutics, Inc. reported initial beneficial ownership for its President and CEO role, consisting of common stock and stock options. Direct holdings include 87,843 shares of Common Stock. The reporting person also has indirect ownership of additional common shares held through three trusts for which the reporting person serves as trustee or co-trustee.
Unexercised stock options to acquire Common Stock include: an option over 23,437 shares at an exercise price of $1.5793 per share expiring on August 16, 2033; an option over 409,709 shares at $3.5302 per share expiring on May 8, 2034; and an option over 370,290 shares at $4.9237 per share expiring on May 17, 2035. Each option vests 25% on the one-year anniversary of its grant date (June 2, 2023; May 9, 2024; and May 18, 2025, respectively), with the remaining shares vesting in equal monthly installments over three years, subject to continued service.
Attovia Therapeutics, Inc. filed an initial beneficial ownership statement for James N. Topper, who is identified as a director of the company. The filing does not list any equity transactions or derivative positions for him. An accompanying exhibit provides a Power of Attorney authorizing certain filing-related actions.
Attovia Therapeutics, Inc. reported the initial equity holdings of Chief Medical Officer Hubert Chen. As of August 4, 2026, he directly holds 2,960 shares of Common Stock and several stock options. These include options over 115,446 and 96,878 shares of Common Stock at an exercise price of $3.5302 per share expiring on May 8, 2034, and an option over 80,731 shares at an exercise price of $4.9237 per share expiring on May 17, 2035. Footnotes state that each option vests over four years: 25% of the underlying shares vested on specified dates in 2025 or 2026, with the remaining 1/48 of the total shares vesting in equal monthly installments over three years, subject to Dr. Chen’s continued service.
Attovia Therapeutics, Inc. reported the initial equity holdings of director John W. Smither. He holds a stock option to purchase 72,792 shares of common stock at an exercise price of $9.29 per share, expiring on July 1, 2036. The option vests over three years, with 33% vesting on July 2, 2027, an additional 33% on July 2, 2028, and the final 33% on July 2, 2029, subject to Mr. Smither’s continued service.